Ovarian Cancer

The FDA has received an NDA for relacorilant for the treatment of patients with platinum-resistant ovarian cancer.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Elizabeth Lee, MD, discusses the future of Rina-S in FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Ou Deng, PhD, discussed findings from a study investigating MSH6-modulated PARP inhibitor sensitivity in BRCA-proficient, high-grade serous ovarian cancer.

Alexander B. Olawaiye, MD, discusses data with relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer that led to the phase 3 ROSELLA trial.

PD-L1 expression was more common in HRD-positive high-grade serous ovarian cancer, indicating potential prognostic value in newly diagnosed cases.

Premal Thaker, MD, discusses findings for IMNN-001 plus perioperative chemotherapy in up-front, advanced ovarian cancer.

Premal H. Thaker, MD, MS, discusses the safety of intraperitoneal administration of IMNN-001 plus neoadjuvant chemotherapy in epithelial ovarian cancer.

The top 5 OncLive videos of the week cover insights in myelofibrosis, lung cancer, ovarian cancer, breast cancer, and melanoma.

Alexander B. Olawaiye, MD, discusses clinical implications of data from the phase 3 ROSELLA trial.

Mirvetuximab soravtansine continues to show efficacy and safety in final analysis of the phase 2 PICCOLO study.

Premal H. Thaker, MD, discusses safety and efficacy data for IMNN-001 plus neoadjuvant chemotherapy in newly diagnosed ovarian cancer.

Rucaparib maintenance improved PFS in HRD-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

Raludotatug deruxtecan showed promising clinical activity in patients with heavily pretreated, platinum-sensitive ovarian cancer.

Deena M. Atieh Graham, MD, discusses notable shifts within the ovarian cancer landscape leading to better patient outcomes.

The FDA granted fast track designation to PHST001 for patients with ovarian cancer.

The FDA has granted accelerated approval to avutometinib/defactinib for KRAS-mutant recurrent low-grade serous ovarian cancer.

Perioperative IMNN-001 plus chemotherapy generated numerical survival improvements in newly diagnosed epithelial ovarian cancer.

Relacorilant plus nab-paclitaxel showed meaningful PFS and OS gains, offering a potential new option for patients with platinum-resistant ovarian cancer.

Dostarlimab/chemotherapy plus maintenance niraparib showed clinically modest PFS improvements vs niraparib alone in newly diagnosed advanced ovarian cancer.

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

Experts from the gynecologic oncology space vote on their most anticipated abstracts on OncLive’s social media.

Experts highlight key abstracts and presentations to keep an eye on in gynecologic oncology at the 2025 ASCO Annual Meeting.

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.

Pembrolizumab/paclitaxel with or without bevacizumab improved PFS vs placebo/chemotherapy with or without bevacizumab in platinum-resistant ovarian cancer.